Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma.
about
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapyPancreatic endocrine neoplasms: a current update on genetics and imaging.Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upGastrointestinal neuroendocrine tumors: pancreatic endocrine tumorsNeuroendocrine tumors of the gastro-entero-pancreatic systemMenin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitusEvaluation of the risk factors associated with rectal neuroendocrine tumors: a big data analytic study from a health screening center.Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogsGene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway.Gastric neuroendocrine tumours.Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review.Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in miceIdentification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors.A multimodal approach to the management of neuroendocrine tumour liver metastasesPhosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advancesGastric acid hypersecretory states: recent insights and advances.Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.Non-functioning pancreatic neuroendocrine tumors--a case report and review of literature.Primary hepatic gastrinoma: Report of a case and review of literatureNeuroendocrine neoplasms of the gut and pancreas: new insights.Pancreatic lesions in von Hippel-Lindau disease? A systematic review and meta-synthesis of the literature.Pancreatic neuroendocrine tumors: a comprehensive review.Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus.Non-functional pancreatic neuroendocrine tumor as an incidentaloma--a case report and review of literature.Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors.The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.Emergence of well differentiated neuroendocrine (carcinoid) tumours following chemoradiotherapy for rectal adenocarcinoma.Expression of PTEN and mTOR in pancreatic neuroendocrine tumors.Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China.
P2860
Q21198871-B90ED095-6117-4E50-AEAB-F9C65F9FB25DQ26852418-6EB46785-B5B1-49E9-B652-8F4A9131C3CCQ28285545-1BECD6B0-3219-4A57-B7B6-675BC08A41D3Q28290833-6C4B4422-30B8-4E38-BE32-B30771E07436Q28294432-13E5FFEC-968E-4953-9A80-6C2DCE910133Q28592973-E38A4020-35E8-406C-88F3-3CC4F9908579Q31064727-A9B2E5A1-954F-4F2E-A39F-18071C66CDB1Q33392694-22505CE2-F86F-4D3C-9534-529FB8EE80CEQ33603032-6FD91578-6B18-495B-B373-B17CB14531F5Q34146539-52665B0E-0A74-4FB5-88AF-3A509E6B5B1DQ34306680-4F36C601-4303-40B7-BD0D-751313DF09BCQ34400151-386D7B03-F548-49A7-BED7-ECF21E6E67D8Q34965132-C8899E9C-2159-4A46-AD91-64F2AA74AA87Q35001777-2CF418E7-4590-4FC0-B748-78CA9E3FFF1EQ35120054-4B0860BA-199C-42B4-AA8E-733706A1A8BDQ35456945-280E72F9-5062-4EEC-ADAB-EA36FAB0335EQ35810562-1CA1ED99-ACDF-43D8-9CBF-0795CF02746CQ36642695-CD3AE6D8-BC22-4E9C-85A7-E049C633CB6BQ37121790-2D88837C-86DA-4718-BD12-50833EA88566Q37125550-9940C803-D2E2-4165-B736-E742B2D1AB2BQ37474172-3B58D03B-74BA-4F31-B4A0-7D19AEA2D715Q37482586-0FD9031A-865E-41E7-9575-45FAC17DEBC0Q37802274-1E9B23F2-44B1-4C81-AC68-383B1DAD2DD6Q37878890-104EEBF5-563F-4821-B423-E639844D13FEQ37909911-30D393B9-A48A-45C4-AD85-F62F5F44B03DQ37988747-36C1A9E0-7F9C-4477-920B-67B4CC8D468AQ37995947-1F26A296-B571-48B6-BED8-3BB44F8CAD83Q38032552-829A6607-A599-4722-9F59-9D94BCB1974FQ38052101-5758052C-C5BB-4C2C-8305-396869589370Q38066186-6BAA2E81-488F-4E4B-A61E-63E0A793C984Q38099268-F730691A-8CB5-475E-B441-04D543181980Q38716228-7013EFA7-2760-4980-AD1B-F91C9A64043EQ42452282-71051CD4-6A62-4A81-81D8-C01228B108E0Q43097453-94BD8E8A-2DC2-4A4E-A2AF-C1ACF7C80868Q45007580-BEBE5E29-39FA-44F9-83B8-9F756ED9A600Q45895236-2110EF97-6002-4814-B5F3-1D06AD915F4DQ50529718-9154FF23-81A4-4BF7-93B0-1797A5896705
P2860
Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma.
@ast
Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma.
@en
type
label
Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma.
@ast
Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma.
@en
prefLabel
Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma.
@ast
Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma.
@en
P1476
Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma.
@en
P2093
James C Yao
P304
P356
10.1016/J.BEEM.2007.01.006
P577
2007-03-01T00:00:00Z